The Enterprise Value as of December 2024 (TTM) for Relay Therapeutics, Inc. (RLAY) is 623.90M

According to Relay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 623.90M. This represents a change of -35.44% compared to the average of 966.35M of the last 4 quarters.

Relay Therapeutics, Inc. (RLAY) Historical Enterprise Value (quarterly & annually)

How has RLAY Enterprise Value performed in the past?

The mean historical Enterprise Value of Relay Therapeutics, Inc. over the last ten years is 854.69M. The current 623.90M Enterprise Value has changed 7.20% with respect to the historical average. Over the past ten years (40 quarters), RLAY's Enterprise Value was at its highest in in the December 2020 quarter at 3.31B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

Relay Therapeutics, Inc. (RLAY) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Relay Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Relay Therapeutics, Inc. (RLAY) Average Enterprise Value

How has RLAY Enterprise Value performed in the past?

The current Enterprise Value of Relay Therapeutics, Inc. (RLAY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Relay Therapeutics, Inc. (RLAY) Enterprise Value vs. Peers

How is RLAY’s Enterprise Value compared to its peers?

Relay Therapeutics, Inc.’s Enterprise Value is greater than Stoke Therapeutics, Inc. (467.23M), less than Pliant Therapeutics, Inc. (792.38M), greater than Black Diamond Therapeutics, Inc. (123.50M), less than Arvinas, Inc. (1.15B), less than Day One Biopharmaceuticals, Inc. (859.59M), less than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), greater than Terns Pharmaceuticals, Inc. (234.86M), less than Apellis Pharmaceuticals, Inc. (4.20B), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than aTyr Pharma, Inc. (138.44M), greater than Century Therapeutics, Inc. (88.73M), less than Blueprint Medicines Corporation (6.12B), greater than C4 Therapeutics, Inc. (294.04M), greater than Monte Rosa Therapeutics, Inc. (356.78M), less than Nurix Therapeutics, Inc. (1.34B), greater than Foghorn Therapeutics Inc. (255.47M), less than Edgewise Therapeutics, Inc. (2.80B), greater than Mineralys Therapeutics, Inc. (502.94M), greater than Cullinan Oncology, Inc. (591.52M),

Build a custom stock screener for Relay Therapeutics, Inc. (RLAY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relay Therapeutics, Inc. (RLAY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.